Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Milestone Pharmaceuticals ( (MIST) ) has shared an update.
At the Annual Meeting, Milestone Pharmaceuticals‘ shareholders voted on five proposals, including the election of directors and the appointment of PricewaterhouseCoopers LLP as the company’s auditor until 2026. The meeting also addressed amendments to the 2019 EIP, executive compensation, and the frequency of advisory votes on executive compensation. These decisions reflect the company’s ongoing governance and operational strategies, impacting its leadership structure and financial oversight.
The most recent analyst rating on (MIST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Milestone Pharmaceuticals stock, see the MIST Stock Forecast page.
Spark’s Take on MIST Stock
According to Spark, TipRanks’ AI Analyst, MIST is a Underperform.
Milestone Pharmaceuticals’ overall stock score reflects substantial financial difficulties, including no revenue and negative cash flows. However, the upcoming launch of CARDAMYST provides a potential turnaround opportunity, which is a significant positive factor. Technical indicators suggest a bearish trend, and valuation metrics highlight the lack of earnings and dividends, indicating a speculative investment.
To see Spark’s full report on MIST stock, click here.
More about Milestone Pharmaceuticals
Average Trading Volume: 2,394,157
Technical Sentiment Signal: Hold
Current Market Cap: $93.56M
Find detailed analytics on MIST stock on TipRanks’ Stock Analysis page.